Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female aged \>/= 18 years with a diagnosis of LAM~* Pulmonary function abnormalities as follows:~* FEV1 of ≤ 80% of the predicted value following administration of a standard dose of a short acting β2-agonist (\*200 µg Salbutamol, measured between 10 and 15 minutes of inhalation) OR~* FEV1 \< 90% of the predicted value of bronchodilator following administration of a standard dose of a short acting β2-agonist (\*200 µg Salbutamol, measured between 10 and 15 minutes of inhalation) and DLco (uncorrected) \<80% predicted.~* Female patients including those of childbearing potential will be included in this study.~* Negative pregnancy test at screening and baseline~Exclusion Criteria:~* FEV1\<50% of predicted post-bronchodilator.~* Change in FVC (ml) \> ± 15% of screening value at baseline visit (not less than 14d after screening visit).~* Use of any medicine containing estrogen in the 4 months prior to the screening visit and for the duration of the study~* Significant hematologic, renal, hepatic laboratory abnormality or amylase \> 1.5x the upper limit of the normal range at the screening or baseline visits~* Fasting blood glucose \> 126mg/dl or random blood glucose \>200mg/dl at screening and/or baseline~* Recent surgery (involving entry into a body cavity or requiring sutures) within 2 months of the screening visit or any evidence of unhealed surgical wound.~* Uncontrolled hyperlipidemia (defined as persistent elevation of total cholesterol or triglycerides \>6.5nM/L) or a history of clinical atherosclerotic disease including heart attack, angina, peripheral vascular disease or stroke.~* Previous organ transplantation~* Inability to give informed consent~* Inability to perform pulmonary function or 6 minute walk tests and imaging assessments~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): All patients received a starting dose of everolimus 2.5mg/day for 4 weeks, followed by a dose of 5 mg/day for 4 weeks and finally a dose of 10mg/day for 18 weeks.~The 26 week treatment period was followed by an optional extension period wherein patients continued therapy until the last patient had completed 26-weeks of treatment. The longest period a patient participated in the study was 62 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).